Previous close | 216.85 |
Open | 216.83 |
Bid | 212.67 x 1000 |
Ask | 217.55 x 1000 |
Day's range | 215.96 - 220.14 |
52-week range | 191.97 - 238.47 |
Volume | |
Avg. volume | 534,820 |
Market cap | 18.193B |
Beta (5Y monthly) | 1.04 |
PE ratio (TTM) | 40.28 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.88 (1.33%) |
Ex-dividend date | 26 Nov 2024 |
1y target est | N/A |
LH is expected to perform strongly in both of its segments and will also likely advance in its strategic priorities.
LH is well-placed for long-term success in Cell & Gene Therapy, expanding into the consumer market and international growth through the specialty testing and biopharma business.
Labcorp's expanding testing solutions in high-growth areas, partnerships and focus on operational efficiency instill optimism.